<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31050">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02702492</url>
  </required_header>
  <id_info>
    <org_study_id>KCP-9274-901</org_study_id>
    <nct_id>NCT02702492</nct_id>
  </id_info>
  <brief_title>PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)</brief_title>
  <acronym>PANAMA</acronym>
  <official_title>A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karyopharm Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, and efficacy of oral KPT-9274 for the
      treatment of patients with advanced solid malignancies or non-Hodgkin's lymphoma (NHL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a first-in-human, multi-center, open-label clinical study with separate Dose
      Escalation and Expansion Phases to assess preliminary safety, tolerability, and efficacy of
      KPT-9274, a dual inhibitor of PAK4 and NAMPT, in patients with advanced solid malignancies
      (including sarcoma, colon, lung, etc.) or NHL for which all standard therapeutic options
      considered useful by the investigator have been exhausted.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>assessed at 8 weeks</time_frame>
    <description>Includes complete response and partial response</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">175</enrollment>
  <condition>NHL</condition>
  <condition>Solid Tumors</condition>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>KPT-9274</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral KPT-9274 three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KPT-9274 &amp; Niacin ER</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg niacin ER co-administered with each dose of oral KPT-9274 three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28 day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KPT-9274</intervention_name>
    <arm_group_label>KPT-9274</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KPT-9274 &amp; Niacin ER</intervention_name>
    <arm_group_label>KPT-9274 &amp; Niacin ER</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced solid malignancies or NHL for which all standard therapeutic options
             considered useful have been exhausted.

          -  Must have objective evidence of progressive disease on study entry.

          -  Advanced solid malignancies: Measureable disease as defined by RECIST 1.1.

          -  NHL: Measureable disease including target lesion(s) as defined by the Lugano
             Classification for initial evaluation and staging.

          -  Must have a site of disease amenable to biopsy and be a candidate for biopsy.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤1.

          -  Dose Expansion Phase (KPT-9274 + niacin ER cohort only): Patient tumors NAPRT1 and
             IDH1 tumor status must be determined at the central laboratory prior to enrollment.

          -  Life expectancy of ≥3 months.

        Exclusion Criteria:

          -  Known central nervous system (CNS) disease or leptomeningeal involvement, regardless
             of response to prior therapy.

          -  Major surgery within 4 weeks before C1D1.

          -  Active infection with completion of therapeutic antibiotics, antivirals, or
             antifungals within one week prior to C1D1. Prophylactic antibiotics, antivirals or
             antifungals are permitted.

          -  Known history of Human Immunodeficiency Virus (HIV); HIV testing is not required as
             part of this study.

          -  Known, active hepatitis A, B, or C infection; or known to be positive for HCV RNA or
             HBsAg (HBV surface antigen).

          -  Significant diseased or obstructed gastrointestinal tract or uncontrolled vomiting or
             diarrhea that could interfere with the absorption of KPT-9274.

          -  Active peptic ulcer disease or other active gastrointestinal bleeds.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kauffman, MD, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Karyopharm Therapeutics Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Kauffman, MD, PhD</last_name>
    <email>mkauffman@karyopharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon Shacham, PhD</last_name>
    <email>sshacham@karyopharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Leong, MD</last_name>
      <email>Stephen.Leong@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Leong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University, Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Pishvaian, MD, PhD</last_name>
      <email>pishvaim@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Pishvaian, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amit Mahipal, MBBS, MPH</last_name>
      <phone>507-293-0462</phone>
      <email>mahipal.amit@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Amit Mahipal, MBBS, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU-Laura &amp; Isaac Perlmutter Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>100016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Cho</last_name>
      <phone>212-731-5871</phone>
      <email>daniel.cho@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Daniel Cho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordan Berlin, MD</last_name>
    </contact>
    <contact_backup>
      <email>Jordan.Berlin@vanderbilt.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jordan Berlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aung Naing</last_name>
      <phone>713-563-0803</phone>
      <email>anaing@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Aung Naing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albiruni Razak, MB, BCh</last_name>
      <phone>416-586-4800</phone>
      <phone_ext>3883</phone_ext>
    </contact>
    <investigator>
      <last_name>Albiruni Razak, MB, Bch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 31, 2017</lastchanged_date>
  <firstreceived_date>March 3, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PAK4</keyword>
  <keyword>KPT-9274</keyword>
  <keyword>Karyopharm</keyword>
  <keyword>NHL</keyword>
  <keyword>solid tumors</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
